ClinicalTrials.gg
CompletedNCT02427568Updated Jun 5, 2025Results posted

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

A Phase 2 interventional study of Midomafetamine HCl and Placebo in Anxiety, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy?

Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy.

  • Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy.
  • Each medication session will be followed by three non-drug integrative therapy sessions.
  • After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session.
  • Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.
Read the detailed description

This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy. Thirteen participants were randomized to the active dose condition of 125 mg of MDMA HCl (plus an optional supplemental dose of 62.5 mg MDMA HCl) with therapy and five participants were randomized to the placebo with therapy condition. The study consisted of two blinded experimental sessions of MDMA-assisted therapy or placebo with therapy, each session lasting six to eight hours and scheduled two to four weeks apart. Each participant was unblinded one month after their second experimental session in Stage 1. After unblinding, participants receiving MDMA were to complete a third open-label experimental session of MDMA-assisted therapy and participants who originally received placebo had the opportunity to cross over to open-label Stage 2 and receive active MDMA-assisted therapy in 3 sessions.

The primary objective of the study is to assess changes in trait anxiety in subjects receiving active dose MDMA compared to those receiving placebo as measured by State-Trait Anxiety Index (STAI) Trait scores from Baseline to the Primary Endpoint (one month after the second experimental session).

02

Conditions studied

  • Anxiety

Browse trials for

Keywords

  • Anxiety
  • MDMA
  • Life-threatening illness
  • Therapy
  • midomafetamine
03

In context

Anxiety Disorders Unverified

7,231 studies on the registry are indexed under Anxiety Disorders; 1,686 are open to participants now.

This study's enrollment of 18 is below the median of 80 across 6,085 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with life-threatening cancer or non-dementing neurological illness, which can be ongoing or in remission, but with a possibility of recurrence
  • Prognosis of at least nine months from the time of screening
  • Have anxiety as a result of facing their illness
  • Are at least 18 years old
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Are willing to commit to medication dosing, experimental sessions, follow-up sessions, and to complete evaluation instruments
  • Are willing to remain overnight at the study site after each experimental session until after the integrative session occurring the next morning
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to select up to three observers who will complete observer measures of subject attitudes and behavior
  • Negative pregnancy test if able to bear children and agree to use effective
  • Are proficient in speaking and reading English
  • Agree to have all psychotherapy sessions recorded to audio/video.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of ;
  • Weigh less than 48 kg
  • Are abusing illegal drugs
  • Are unable to give adequate
  • Upon review of past, current drugs/medication must not be on or have taken a medication that is exclusionary
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study
  • Have used "Ecstasy" (material represented as containing MDMA) at least once within twelve months of enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Placebo comparator
    Placebo with therapy

    Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.

    Drug: Placebo · Behavioral: Therapy

  • Experimental
    MDMA-assisted therapy (125 mg)

    125 mg midomafetamine HCl administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg.

    Drug: Midomafetamine HCl · Behavioral: Therapy

Interventions

  • Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.

    Also known as: 3,4-methylenedioxymethamphetamine, Midomafetamine, MDMA

  • DrugPlacebo

    Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.

    Also known as: Inactive placebo

  • BehavioralTherapy

    Manualized therapy

06

What researchers measure

Primary outcomes

  1. Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint

    The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  2. Primary Endpoint STAI Trait Score

    The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

    Time frame: One month post-2nd experimental session

Secondary outcomes

  1. Change in STAI State Score From Baseline to Primary Endpoint

    The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  2. Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint

    The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  3. Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

    The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)

  4. Change in MADRS Score From Baseline to Primary Endpoint

    The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, \> 34 severe depression. Higher scores indicate greater severe depression.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  5. Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint

    The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  6. Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

    The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  7. Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint

    The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  8. Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint

    The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death. The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  9. Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint

    The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses. A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.

    Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

07

Results

Posted Aug 2, 2021

Participant flow

Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, and through word of mouth.

Participant flow — Overall Study
MilestonePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Started513
Completed513
Not completed00

Outcome measures

PrimaryChange in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint

The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint-8.8 ± 14.7-23.5 ± 13.2
PrimaryPrimary Endpoint STAI Trait Score

The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

Time frame:
One month post-2nd experimental session
Reported as:
Mean · score on a scale
Primary Endpoint STAI Trait Score
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Primary Endpoint STAI Trait Score48.6 ± 12.638.9 ± 10.6
SecondaryChange in STAI State Score From Baseline to Primary Endpoint

The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in STAI State Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in STAI State Score From Baseline to Primary Endpoint-6.0 ± 15.8-22.1 ± 17.9
SecondaryChange in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint

The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint-14.6 ± 8.6-20.9 ± 13.8
SecondaryChange in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint3.0 ± 12.56.6 ± 9.7
SecondaryChange in MADRS Score From Baseline to Primary Endpoint

The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, \> 34 severe depression. Higher scores indicate greater severe depression.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in MADRS Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in MADRS Score From Baseline to Primary Endpoint-7.0 ± 7.2-10.5 ± 8.2
SecondaryChange in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint

The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint-0.2 ± 1.3-3.6 ± 5.4
SecondaryChange in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint-2.6 ± 6.112.9 ± 23.2
SecondaryChange in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint

The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Physical well-being2.8 ± 5.01.4 ± 4.4
Social/ family well-being-2.0 ± 2.90.8 ± 3.4
Emotional well-being1.0 ± 2.21.6 ± 7.1
Functional well-being1.0 ± 1.64.8 ± 5.8
Additional concerns-0.3 ± 5.04.5 ± 11.9
SecondaryChange in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint

The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death. The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Fear of death-0.6 ± 1.0-0.1 ± 0.6
Death avoidance-1.1 ± 1.80 ± 0.8
Neutral acceptance0.2 ± 0.60.1 ± 0.6
Approach acceptance-0.1 ± 1.10.3 ± 0.7
Escape acceptance0 ± 0.90.4 ± 1.0
SecondaryChange in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint

The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses. A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.

Time frame:
Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Reported as:
Mean · score on a scale
Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy (125 mg)
Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint-0.04 ± 0.50.4 ± 0.7

Adverse events

Collected over Adverse events were collected throughout the study: up to 2 months after the 2nd experimental session (for Stage 1 blinded for placebo group), at the end of Stage 1 (for MDMA group), up to 2 months after the 3rd experimental session (for Stage 2 crossover group), and at 12-month study follow-up (approximately 1 year following the 3rd MDMA session [following Stage 1 for participants in the MDMA arm and following crossover to Stage 2 for the Stage 1 placebo group] .. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo With Therapy (Blinded)0/5 (0%)0/5 (0%)2/5 (40%)
MDMA-assisted Therapy (125 mg) (Blinded)0/13 (0%)0/13 (0%)11/13 (84.6%)
Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg)0/5 (0%)0/5 (0%)4/5 (80%)
MDMA Group Open-label MDMA-assisted Therapy (125 mg)0/13 (0%)0/13 (0%)3/13 (23.1%)
Placebo With Therapy Group 12-month Follow-up0/5 (0%)0/5 (0%)2/5 (40%)
MDMA-assisted Therapy Group 12-month Follow-up1/13 (7.7%)3/13 (23.1%)3/13 (23.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo With Therapy (Blinded)MDMA-assisted Therapy (125 mg) (Blinded)Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg)MDMA Group Open-label MDMA-assisted Therapy (125 mg)Placebo With Therapy Group 12-month Follow-upMDMA-assisted Therapy Group 12-month Follow-up
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/130/50/130/51/13
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/130/50/130/51/13
Cerebrovascular accidentNervous system disorders0/50/130/50/130/51/13
Spinal cord paralysisNervous system disorders0/50/130/50/130/51/13
ChordomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/130/50/130/51/13
MeningitisInfections and infestations0/50/130/50/130/51/13
SepsisInfections and infestations0/50/130/50/130/51/13
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPlacebo With Therapy (Blinded)MDMA-assisted Therapy (125 mg) (Blinded)Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg)MDMA Group Open-label MDMA-assisted Therapy (125 mg)Placebo With Therapy Group 12-month Follow-upMDMA-assisted Therapy Group 12-month Follow-up
InsomniaPsychiatric disorders1/54/132/52/131/50/13
FatigueGeneral disorders0/53/130/50/130/50/13
AnxietyPsychiatric disorders0/51/131/51/130/50/13
Depressed moodPsychiatric disorders0/51/131/50/130/50/13
DepressionPsychiatric disorders0/51/130/50/131/50/13
PainGeneral disorders0/51/131/50/130/50/13
UrticariaSkin and subcutaneous tissue disorders0/51/131/50/130/50/13
Chest PainGeneral disorders1/50/130/50/130/50/13
Muscle SpasmMusculoskeletal and connective tissue disorders1/50/130/50/130/50/13
Neuropathy peripheralNervous system disorders1/50/131/50/131/50/13

Baseline characteristics

Intent-to-treat (ITT) set

Age, Continuous
Age, Continuous(years)Placebo With TherapyMDMA-assisted Therapy (125 mg)Total
Mean53.2 ± 10.555.5 ± 7.054.9 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo With TherapyMDMA-assisted Therapy (125 mg)Total
Female41014
Male134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo With TherapyMDMA-assisted Therapy (125 mg)Total
Race — White/Caucasian31215
Race — Black/African American101
Race — Other112
Baseline State-Trait Anxiety Inventory Trait (STAI-T)
Baseline State-Trait Anxiety Inventory Trait (STAI-T)(units on a scale)Placebo With TherapyMDMA-assisted Therapy (125 mg)Total
Mean62.5 ± 7.3157.4 ± 5.1861.1 ± 7.03
08

Study locations

1 site
  • Offices of Philip Wolfson MD
    San Anselmo, California 94960, United States
09

References and documents

Publications

  • Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, Carlin SC, Sola E, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020 Nov 24;10(1):20442. doi: 10.1038/s41598-020-75706-1. PubMed 33235285 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available when all participants have completed the study, and when data has been quality checked and locked.

Access criteria: Interested persons should correspond with the central contact for the multisite study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Apr 2017, 23 months.

Results were first posted in Aug 2021, 4 years 3 months after primary completion. A results delay was requested in Jun 2020.

Of 96 phase 2 interventional studies under Anxiety Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2015
First posted
Apr 28, 2015
StartActual
May 14, 2015
Primary completionActual
Apr 25, 2017
CompletionActual
May 17, 2018
Results delay requested
Jun 19, 2020
Results first posted
Aug 2, 2021
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02427568
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Apr 28, 2015
Start date
May 14, 2015
Primary completion
Apr 25, 2017
Completion
May 17, 2018
Results posted
Aug 2, 2021
Last update
Jun 5, 2025

Study contacts

Philip Wolfson, MD
principal investigator · Private Practice

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion